On Monday shares of Upland Software, Inc. (NASDAQ:UPLD) closed at $6.63. Company’s EPS growth for next 5 years is recorded as 20.00%. Upland Software, Inc. (NASDAQ:UPLD), announced that it will release financial results for the first quarter of 2015 on Thursday, May 14, 2015 after the market closes.
Delta Air Lines, Inc. (NYSE:DAL) in last trading activity advanced 1.39% to close at $46.81. Company weekly performance is 3.57% while its quarterly performance stands at 5.74%. Delta Air Lines, Inc. (NYSE:DAL) is -7.95% away from its 52 week high. JPMorgan Chase & Co. reissued their overweight rating on shares of Delta Air Lines (NYSE:DAL) in a research note released on Saturday morning. They currently have a $71.50 target price on the stock, down from their previous target price of $80.50.
On Monday shares of Pall Corporation (NYSE:PLL) closed at $99.31. Company’s sales growth for last 5 years was 3.70% and EPS growth for next 5 years is recorded as 12.80%. Water and air filter maker Pall Corp (NYSE:PLL) is in the final stages of an auction that could value the company at more than $10 billion, the Wall Street Journal reported on Monday.
Google Inc (NASDAQ:GOOG) in last trading activity decreased -0.47% to close at $535.70. Company weekly performance is -0.94% while its quarterly performance stands at 1.49%. Google Inc (NASDAQ:GOOG) is -52.11% away from its 52 week high. Google Inc. (NASDAQ:GOOG) said its self-driving vehicles were involved in 11 minor accidents in the past six years that they have test-driven. However, the vehicles were not to blame for the incidents that included light damage and no injuries, the company added.
On last trading day Mylan N.V. (NASDAQ:MYL) increased 0.45% to close at $71.63. Its volatility for the week is 2.96% while volatility for the month is 3.87%. MYL’s sales growth for past 5 years was 8.70% and its EPS growth for past 5 years was 52.70%. Mylan N.V. (NASDAQ:MYL) monthly performance is 1.98%. Mylan N.V. (NASDAQ:MYL) has been unwilling to sell itself to rival Teva Pharmaceuticals Industries. But Reuters reported that Mylan Executive Chairman Robert Coury told investors that he would consider buying Teva down the road.